

Publication of Issue Price Information Pursuant to Treas. Reg. §1.1273-2(f)(9)

December 4, 2019

Cigna Corporation (“Cigna”) is publishing this notice, pursuant to the requirements of Treas. Reg. §1.1273-2(f)(9) (the “Regulations”), with respect to the settlement of its offer to exchange any and all of certain outstanding notes (collectively, the “Old Notes”) issued by Cigna's wholly-owned subsidiaries: Cigna Holding Company, Express Scripts Holding Company and Medco Health Solutions, Inc. (collectively, the “Subsidiary Issuers”) for new senior notes issued by Cigna (collectively, the “New Notes”) and cash pursuant to the terms and conditions set forth in Cigna’s offering memorandum and consent solicitation statement, dated as of September 26, 2019.

Cigna has determined that 19 of the 23 series of New Notes (listed below) are publicly traded within the meaning of the Regulations and has determined the fair market value and issue price of each of the 19 series of New Notes (expressed as a percentage of the principal amount of the New Notes) to be as stated below.

Title of Series of New Notes	Subsidiary Issuer	CUSIP Number	Fair Market Value/Issue Price of New Notes
New Cigna 4.500% Notes Due 2021	Cigna Holding Company	125523AL4	103.16%
New Cigna 4.000% Notes due 2022	Cigna Holding Company	125523AN0	103.77%
New Cigna 3.250% Notes due 2025	Cigna Holding Company	125523AU4	103.11%
New Cigna 7.875% Notes due 2027	Cigna Holding Company	125523AW0	129.65%
New Cigna 3.050% Notes due 2027	Cigna Holding Company	125523AY6	100.28%
New Cigna 6.150% Notes due 2036	Cigna Holding Company	125523BC3	120.47%
New Cigna 5.375% Notes due 2042	Cigna Holding Company	125523BG4	115.20%
New Cigna 3.875% Notes due 2047	Cigna Holding Company	125523BJ8	95.95%
New Cigna 3.300% Notes due 2021	Express Scripts Holding Company	125523BL3	101.40%
New Cigna 4.750% Notes due 2021	Express Scripts Holding Company	125523BN9	105.13%
New Cigna 3.900% Notes due 2022	Express Scripts Holding Company	125523BQ2	103.61%
New Cigna 3.050% Notes due 2022	Express Scripts Holding Company	125523BS8	102.16%

New Cigna 3.000% Notes due 2023	Express Scripts Holding Company	125523BU3	102.05%
New Cigna 3.50% Notes due 2024	Express Scripts Holding Company	125523BW9	104.21%
New Cigna 4.500% Notes due 2026	Express Scripts Holding Company	125523BY5	108.88%
New Cigna 3.400% Notes due 2027	Express Scripts Holding Company	125523CA6	102.63%
New Cigna 6.125% Notes due 2041	Express Scripts Holding Company	125523CC2	124.87%
New Cigna 4.800% Notes due 2046	Express Scripts Holding Company	125523CE8	110.27%
New Cigna 4.125% Notes due 2020	Medco Health Solutions, Inc.	125523CG3	101.74%

Cigna has determined that 1 of the 23 series of New Notes (listed below) is not publicly traded within the meaning of the Regulations but that the corresponding series of Old Notes was publicly traded and accordingly has determined the fair market value of such Old Notes and the issue price of the corresponding New Notes (expressed as a percentage of the principal amount of the New Notes) to be as stated below.

Title of Series of New Notes	Subsidiary Issuer	CUSIP Number	Fair Market Value of Old Notes/Issue Price of New Notes
New Cigna 5.875% Notes due 2041	Cigna Holding Company	125523BE9	121.84%

Cigna has determined that the remaining 3 of 23 series of New Notes (listed below) are not publicly traded and were not issued in exchange for publicly traded Old Notes. Accordingly, it is expected that such New Notes generally will have an issue price equal to their principal amount, reduced by any accrued interest on the corresponding series of Old Notes on the date of the exchange.

Title of Series of New Notes	Subsidiary Issuer	CUSIP Number
New Cigna 8.30% Notes due 2023	Cigna Holding Company	125523AQ3
New Cigna 7.65% Notes due 2023	Cigna Holding Company	125523AS9
New Cigna 8.30% Step-Down Notes due 2033	Cigna Holding Company	125523BA7

This notice is only intended to fulfill Cigna's notification obligation under the Regulations and does not constitute tax advice. Cigna advises each holder of the New Notes to obtain

professional tax advice to determine the implications of this notification on the determination of the holder's income tax liabilities.